LONDON -- Scancell Holdings (LSE:SCLP) reported first-half figures today, and brought us news of "encouraging preliminary results from part 1 of the Phase 1/2 clinical trial" for its lead vaccine SCIB1.
The developer of therapeutic cancer vaccines said that initial signs show evidence that the vaccine is producing an immune response in cancer patients, which "may also be associated with clinical benefit."
In view of the positive results and minimal side effects seen with the 4mg dose, Scancell has received approval to evaluate an 8mg dose in an extra group of patients, in parallel with part 2 of the phase 1/2 trial.
The vaccines are based on Scancell's patented ImmunoBody platform, approved in Europe, Australia and now the United States.
Scancell's chairman commented:
The company has also announced the development of a new platform technology, Moditope™, which the directors believe could have a profound effect on the way that cancer vaccines are developed.
Moditope stimulates the production of killer CD4 T cells with powerful anti-tumour activity, with management saying: "CD4 responses to cancer associated antigens have been notoriously difficult to generate whether presented as peptides, proteins or DNA. Scancell has identified and patented a series of modified epitopes that overcome this limitation."
The shares dropped off by 1% to 39 pence this morning, following news that Scancell made a loss of 923,020 pounds compared to H1 2011's loss of 893,404 pounds, with the balance sheet dipping to 2.57 billion pounds at Oct. 31, 2012, from 3.53 billion pounds at as of April 30, 2012.
However, 2012 was the year that saw the emergence of Scancell as an investment prospect, soaring from a low near the beginning of the year of 4.75 pence to finish 2012 near a high of 60 pence -- over a 12-fold increase! With the shares having fallen back slightly to hover around 40 pence, further successful tests in 2013 could see another giant leap in the shares' value.
Many private investors can only dream of gains like that. But if you read this special free report compiled by analysts here at The Motley Fool, you can find out how investing in unloved shares-- such as Scancell at the beginning of 2012 -- can produce fantastic gains if they recover strongly.
Sam Robson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.